ATE483473T1 - Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs - Google Patents

Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs

Info

Publication number
ATE483473T1
ATE483473T1 AT04450149T AT04450149T ATE483473T1 AT E483473 T1 ATE483473 T1 AT E483473T1 AT 04450149 T AT04450149 T AT 04450149T AT 04450149 T AT04450149 T AT 04450149T AT E483473 T1 ATE483473 T1 AT E483473T1
Authority
AT
Austria
Prior art keywords
antibodies
against cancer
low dose
vaccinate against
antibody
Prior art date
Application number
AT04450149T
Other languages
English (en)
Inventor
Hans Loibner
Gottfried Himmler
Manfred Schuster
Original Assignee
Altropus Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933149&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE483473(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altropus Gmbh filed Critical Altropus Gmbh
Application granted granted Critical
Publication of ATE483473T1 publication Critical patent/ATE483473T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04450149T 2004-07-20 2004-07-20 Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs ATE483473T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04450149A EP1618890B1 (de) 2004-07-20 2004-07-20 Verwendung von Antikörpern in einer sehr geringen Dosis zur Impfung gegen Krebs

Publications (1)

Publication Number Publication Date
ATE483473T1 true ATE483473T1 (de) 2010-10-15

Family

ID=34933149

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04450149T ATE483473T1 (de) 2004-07-20 2004-07-20 Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs

Country Status (4)

Country Link
US (1) US20060018901A1 (de)
EP (1) EP1618890B1 (de)
AT (1) ATE483473T1 (de)
DE (1) DE602004029455D1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
WO2011063133A1 (en) * 2009-11-18 2011-05-26 Auburn University LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE
JP6216301B2 (ja) 2014-09-19 2017-10-18 ミネベアミツミ株式会社 照明装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1044487B (zh) * 1999-01-13 2005-09-16 伊格尼昂癌症治疗研发股份公司 抗体用於抗癌接种的用途

Also Published As

Publication number Publication date
US20060018901A1 (en) 2006-01-26
EP1618890A1 (de) 2006-01-25
EP1618890B1 (de) 2010-10-06
DE602004029455D1 (de) 2010-11-18

Similar Documents

Publication Publication Date Title
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
FI1897548T4 (fi) T-solujen säätely
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
DE50000243D1 (de) Verwendung von antikörpern zur vakzinierung gegen krebs
DE60138641D1 (de) Herstellung von mikrokügelchen
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
CY1108691T1 (el) Πολυπεπτιδια
CR10295A (es) "formulacion de un anticuerpo monoclonal humano anti-igf-1r"
ATE521366T1 (de) Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
DE60217698D1 (de) Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex
DE602004024902D1 (de) Verbesserte formulierung zur bereitstellung eines magensaftresitenten beschichtungsmaterials
NO20012135D0 (no) Forsterkede vaksiner
EP4389771A4 (de) Fusionsprotein mit anti-tigit-antikörper und tgf-beta-r sowie pharmazeutische zusammensetzung und verwendung davon
ATE483473T1 (de) Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs
EP1979010A4 (de) Biologische wundversorgung und herstellungsverfahren dafür
EP1870456A4 (de) Verfahren zur herstellung eines gegen ein zellmembranoberflächenantigenepitop gerichteten antikörpers und testverfahren
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
DE112005001260A5 (de) Antigen des PM-2 Antikörpers und dessen Verwendung
ATE526035T1 (de) Tollwut-impfstoff
WO2008046615A3 (en) Anti-ige vaccines
ATE552839T1 (de) Pharmazeutische verwendung von immunologisch mit diphtherie-toxin korrelierten proteinmolekülen
CY1115868T1 (el) Μορια αντισωματων που εχουν ειδικο χαρακτηρα για το ανθρωπινο il-6

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1618890

Country of ref document: EP